Publication of Vical Incorporated's H5N1 Results Paves the Way for H1N1 Clinical Trial
SAN DIEGO, Feb. 24, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the publication in the online edition of Vaccine1 detailed data from two Phase 1 trials of the company's Vaxfectin®-adjuvanted DNA vaccines for H5N1 (avian-origin) influenza, demonstrating the potential of DNA vaccines for rapid deployment in future pandemics.